Dapagliflozin-Associated Diabetic Ketoacidosis
- 1 November 2018
- journal article
- letter
- Published by Ovid Technologies (Wolters Kluwer Health) in Clinical Journal of Sport Medicine
- Vol. 25 (6), e765-e766
- https://doi.org/10.1097/mjt.0000000000000770
Abstract
No abstract availableThis publication has 10 references indexed in Scilit:
- Ketoacidosis associated with SGLT2 inhibitor treatment: Analysis of FAERS dataDiabetes/Metabolism Research and Reviews, 2017
- Euglycemic Diabetic Ketoacidosis With Prolonged Glucosuria Associated With the Sodium-Glucose Cotransporter-2 CanagliflozinJournal of Investigative Medicine High Impact Case Reports, 2017
- SGLT2 Inhibitors: A Systematic Review of Diabetic Ketoacidosis and Related Risk Factors in the Primary LiteraturePharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2017
- Atypical Ketoacidosis and Protracted Hyperglycosuria after Treatment with Ipragliflozin, an SGLT2 InhibitorInternal Medicine, 2017
- American Association of Clinical Endocrinologists and American College of Endocrinology Position Statement on the Association of SGLT-2 Inhibitors and Diabetic KetoacidosisEndocrine Practice, 2016
- Sodium-glucose Cotransporter 2 Inhibitor–induced Diabetic Ketoacidosis in a Type 2 Diabetic PatientThe American Journal of the Medical Sciences, 2016
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 DiabetesThe New England Journal of Medicine, 2015
- SGLT inhibition and euglycaemic diabetic ketoacidosisThe Lancet Diabetes & Endocrinology, 2015
- SGLT inhibitors in management of diabetesThe Lancet Diabetes & Endocrinology, 2013
- A method for estimating the probability of adverse drug reactionsClinical Pharmacology & Therapeutics, 1981